ArticleAnnals of medicine2025
Efficacy of emapalumab in treating 3 pediatric patients with epstein-barr virus-associated hemophagocytic lymphohistiocytosis complicated by multiple organ dysfunction.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07538336 (Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveEpstein-Barr virus-associated hemophagocytic lympho-histiocytosis (EBV-HLH) is common among HLH in paediatric patients, severe cases are often complicated by multiple organ dysfunction syndrome (MODS), leading to poor prognosis and high mortality rate. Emapalumab, an interferon (IFN)-γ inhibitor, can effectively improve patient prognosis without MODS, but it remains unclear whether patients with MODS can achieve clinical benefits. In this study, we aim to evaluate the efficacy and safety of emapalumab in treating EBV-HLH with MODS.
methodsThe paediatric cases admitted to the paediatric intensive care unit were prospectively included, with worsening labs and IFN-γ > 500 pg/mL after standard care, and were given intravenous infusions of emapalumab at a dose of 1-2 mg/kg. Outcomes measured included body temperature, lab results, in-hospital mortality, and stem cell transplant rates.
resultsThree paediatric cases were included, and treatment was uninterrupted. Among these, Case 2 exhibited refractory EBV-HLH. After conventional therapy, the laboratory parameters, hyperthermia and pSOFA score remained unimproved withthe blood IFN-γ > 500 pg/mL. Emapalumab infusion was administered, with significant improvement within one week. Case 2 later developed a cytomegalovirus infection, leading to treatment discontinuation despite stable IFN-γ level. Cases 1 and 3 remained stable without additional treatments during a one-year follow-up.
conclusionThe use of emapalumab to treat paediatric patients with EBV-HLH complicated by MODS can significantly improve body temperature and HLH-related laboratory parameters, but the overall clinical benefit for refractory cases remains unclear. During treatment, it is essential to keep vigilance against concurrent infections, and monitoring for potential latent pathogens is also warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.